Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NATUS MEDICAL INCORPORATED

(NTUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Natus Medical Incorporated : Awarded Key New Government Contract

09/27/2021 | 04:30pm EST

PLEASANTON, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, is pleased to announce the award of a 5-year contract to include Natus Patient Monitoring and Capital Equipment (PMCE) in the electronic catalog (ECAT). The PMCE contract is pre-established and pre-vetted by the Defense Logistics Agency (DLA) as a source for medical equipment and acts as a preferred purchasing source for United States government healthcare systems. ECAT, as an on-line ordering, distribution and payment solution facilitates over $1B in purchase activity annually.

The PMCE contract and ECAT integration will now provide easier access for the Department of Defense (DoD) and Veterans Affairs (VA) health systems to purchase many products across the Natus portfolio, including neurodiagnostic, audiology and newborn care equipment and supplies. The initial 5-year contract term also includes an additional 5-year extension option.

“We are excited to achieve this important milestone,” says Jonathan Kennedy, Natus CEO. “This agreement and Natus inclusion in the electronic catalog solution will dramatically improve the transaction process, making it easier for us to partner with government healthcare systems and provide our innovative solutions to the United States veteran and active-duty military patients in need.”  

About Natus Medical Incorporated

Natus Medical Incorporated improves patient outcomes using the most comprehensive product solutions, depth of training and continuing customer care when diagnosing and treating central nervous and sensory system disorders for patients of all ages.

Additional information about Natus Medical Incorporated can be found at https://natus.com.

Contacts:
Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com                


Primary Logo

Source: Natus Medical Incorporated

2021 GlobeNewswire, Inc., source Press Releases

All news about NATUS MEDICAL INCORPORATED
11/05NATUS MEDICAL INC Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/04NATUS MEDICAL : Q3 Earnings Snapshot
AQ
11/04Natus Medical Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/04Natus Medical Posts Higher Q3 Adjusted Earnings, Revenue; Narrows Full-Year Revenue Out..
MT
11/04GUIDANCE : (NTUS) NATUS MEDICAL INCORPORATED Expects Fiscal Year 2021 EPS Range $1.13 - $1..
MT
11/04GUIDANCE : (NTUS) NATUS MEDICAL INCORPORATED Expects Q4 EPS Range $0.41 - $0.46
MT
11/04Earnings Flash (NTUS) NATUS MEDICAL INCORPORATED Reports Q3 EPS $0.28, vs. Street Est o..
MT
11/04Earnings Flash (NTUS) NATUS MEDICAL INCORPORATED Reports Q3 Revenue $113.9M, vs. Street..
MT
11/04Natus Medical Announces Third Quarter 2021 Financial Results
AQ
11/04Natus Medical Incorporated Reports Earnings Results for the Third Quarter and Nine Mont..
CI
More news
Financials (USD)
Sales 2021 471 M - -
Net income 2021 23,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 33,3x
Yield 2021 -
Capitalization 787 M 787 M -
Capi. / Sales 2021 1,67x
Capi. / Sales 2022 1,62x
Nbr of Employees 1 420
Free-Float 98,4%
Chart NATUS MEDICAL INCORPORATED
Duration : Period :
Natus Medical Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATUS MEDICAL INCORPORATED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 23,29 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Jonathan A. Kennedy President, Chief Executive Officer & Director
Benjamin Drew Davies Chief Financial Officer & Executive Vice President
Joshua H. Levine Non-Executive Chairman
D. Christopher Chung Chief Medical Officer & VP-Regulatory Affairs
Ivan Pandiyan Vice President-Research & Development
Sector and Competitors